PL3965739T3 - Postacie dawkowane będące tabletkami oleilofosfocholiny - Google Patents
Postacie dawkowane będące tabletkami oleilofosfocholinyInfo
- Publication number
- PL3965739T3 PL3965739T3 PL20719972.0T PL20719972T PL3965739T3 PL 3965739 T3 PL3965739 T3 PL 3965739T3 PL 20719972 T PL20719972 T PL 20719972T PL 3965739 T3 PL3965739 T3 PL 3965739T3
- Authority
- PL
- Poland
- Prior art keywords
- oleylphosphospholine
- dosage forms
- tablet dosage
- tablet
- forms
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19168885 | 2019-04-12 | ||
| PCT/EP2020/060324 WO2020208230A1 (en) | 2019-04-12 | 2020-04-10 | Tablet dosage formulations of oleyl phosphocholine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3965739T3 true PL3965739T3 (pl) | 2025-01-13 |
Family
ID=66175207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20719972.0T PL3965739T3 (pl) | 2019-04-12 | 2020-04-10 | Postacie dawkowane będące tabletkami oleilofosfocholiny |
| PL20788798.5T PL4132472T3 (pl) | 2019-04-12 | 2020-10-09 | Granulaty zawierające oleilofosfocholinę |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20788798.5T PL4132472T3 (pl) | 2019-04-12 | 2020-10-09 | Granulaty zawierające oleilofosfocholinę |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12214081B2 (pl) |
| EP (2) | EP3965739B1 (pl) |
| BR (1) | BR112021020389A2 (pl) |
| CA (2) | CA3136525A1 (pl) |
| ES (2) | ES2989158T3 (pl) |
| HR (2) | HRP20241585T1 (pl) |
| PL (2) | PL3965739T3 (pl) |
| WO (2) | WO2020208230A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230129661A (ko) * | 2022-03-02 | 2023-09-11 | 주식회사 코피텍 | Uv 레이져 인쇄에 적합한 필름 코팅을 위한 착색제 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290769A (en) * | 1989-09-27 | 1994-03-01 | Asta Pharma Aktiengesellschaft | Use of hexadecylphosphocholine for the treatment of psoriasis |
| IL136196A (en) | 1998-01-22 | 2004-07-25 | Zentaris Ag | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| KR101418267B1 (ko) * | 2006-02-09 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | Ｃｅｔｐ 억제제의 중합체 제형 |
| CA2818194A1 (en) | 2010-11-22 | 2012-05-31 | Dafra Pharma Research&Development Bvba | Solid dosage forms of oleyl phosphocholine |
| EP3156047A1 (en) * | 2015-10-12 | 2017-04-19 | Sandoz Ag | Afatinib-containing formulation |
-
2020
- 2020-04-10 US US17/603,024 patent/US12214081B2/en active Active
- 2020-04-10 WO PCT/EP2020/060324 patent/WO2020208230A1/en not_active Ceased
- 2020-04-10 BR BR112021020389A patent/BR112021020389A2/pt unknown
- 2020-04-10 EP EP20719972.0A patent/EP3965739B1/en active Active
- 2020-04-10 PL PL20719972.0T patent/PL3965739T3/pl unknown
- 2020-04-10 ES ES20719972T patent/ES2989158T3/es active Active
- 2020-04-10 CA CA3136525A patent/CA3136525A1/en active Pending
- 2020-04-10 HR HRP20241585TT patent/HRP20241585T1/hr unknown
- 2020-10-09 CA CA3179736A patent/CA3179736A1/en active Pending
- 2020-10-09 WO PCT/EP2020/078476 patent/WO2021204409A1/en not_active Ceased
- 2020-10-09 EP EP20788798.5A patent/EP4132472B1/en active Active
- 2020-10-09 PL PL20788798.5T patent/PL4132472T3/pl unknown
- 2020-10-09 HR HRP20250559TT patent/HRP20250559T1/hr unknown
- 2020-10-09 ES ES20788798T patent/ES3024632T3/es active Active
-
2021
- 2021-10-09 US US17/917,572 patent/US20230147712A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3179736A1 (en) | 2021-10-14 |
| WO2020208230A1 (en) | 2020-10-15 |
| HRP20250559T1 (hr) | 2025-07-04 |
| EP3965739C0 (en) | 2024-07-10 |
| EP4132472B1 (en) | 2025-03-26 |
| US20230147712A1 (en) | 2023-05-11 |
| EP3965739A1 (en) | 2022-03-16 |
| CA3136525A1 (en) | 2020-10-15 |
| HRP20241585T1 (hr) | 2025-01-31 |
| EP4132472C0 (en) | 2025-03-26 |
| US20220183975A1 (en) | 2022-06-16 |
| ES2989158T3 (es) | 2024-11-25 |
| PL4132472T3 (pl) | 2025-08-11 |
| WO2021204409A1 (en) | 2021-10-14 |
| EP3965739B1 (en) | 2024-07-10 |
| ES3024632T3 (en) | 2025-06-04 |
| EP4132472A1 (en) | 2023-02-15 |
| US12214081B2 (en) | 2025-02-04 |
| BR112021020389A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3935068T3 (da) | Abirateron-prodrugs | |
| EP3689892A4 (en) | RADIOACTIVE MEDICINAL PRODUCT | |
| IL282330A (en) | Therapeutic compounds | |
| DK3920890T3 (da) | Oral cannabinoid-tablet | |
| IL283900A (en) | Pharmaceutical combinations | |
| EP3785698A4 (en) | Edaravone pharmaceutical composition | |
| MA44720A (fr) | Comprimés à désintégration orale | |
| EP3756639C0 (en) | TABLET CASSETTE | |
| EP3634358C0 (en) | TABLET DISPENSER | |
| PL4003293T3 (pl) | Rozwój farmaceutyczny | |
| EP3486117A4 (en) | TABLE UNIT | |
| EP3826609A4 (en) | Expanding structured dosage form | |
| EP3881897A4 (en) | LAXATIVE IN TABLET FORM | |
| EP3915251A4 (en) | Size dependent inter coding | |
| EP3810063A4 (en) | Individual dose pack | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| EP4018992C0 (en) | TABLET DISPENSING MACHINE | |
| IL269169A (en) | Novel dosage form | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| DK3641919T3 (da) | Doseringsanordning | |
| EP4059502A4 (en) | BUCCAL DISPLACEMENT TABLET | |
| HUE062772T2 (hu) | Hüvelyi tabletta készítmény | |
| PT3949952T (pt) | Composição farmacêutica | |
| DK3285715T3 (da) | Medikamentdoseringspilleudskubningsmekanisme | |
| EP3881841A4 (en) | PHARMACEUTICAL COMPOSITION |